I think people would laugh at me if I put my valuation on it.
$50 was a target for the end of this year. That's quite within reach upon positive phase II results and NV-07a deal. Investors still don't know about NRT's technology base and the various drugs in the pipeline.
When Phenoxodiol and NV-07a get accepted by the Pharmaceutical industry and Investors then NV-04 will get alot more attention. Novogen said this is close to happening which could spark more "Yale" type research deals for NV-04. Eventually that will lead to share price gains. In the mean time we need some good Phase II results, doesn't have to be 100% effective yet as they still need to find the best way/dose to use the drug. Whether in combo with Cisplatin or as a stand alone drug. As long as we see some effect then we know it can only get better.
